-+ 0.00%
-+ 0.00%
-+ 0.00%

Dyne Therapeutics Q3 EPS $(1.06) Misses $(0.92) Estimate

Benzinga·11/05/2026 13:37:53
Listen to the news
Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $(0.92) by 15.22 percent. This is a 39.47 percent decrease over losses of $(0.76) per share from the same period last year.